NCT03386942: A Study of MORAb-202 in Participants With Solid Tumors

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: FRA
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patient must have tumor(s) that are folate receptor alpha (FRA)+
Exclusions: Participants with brain or subdural metastases are not eligible, unless they have completed local therapy- see trial for details

Up ↑